GB2432526A - Use of ifenprodil for the treatment of ophthalmic diseases - Google Patents
Use of ifenprodil for the treatment of ophthalmic diseases Download PDFInfo
- Publication number
- GB2432526A GB2432526A GB0523961A GB0523961A GB2432526A GB 2432526 A GB2432526 A GB 2432526A GB 0523961 A GB0523961 A GB 0523961A GB 0523961 A GB0523961 A GB 0523961A GB 2432526 A GB2432526 A GB 2432526A
- Authority
- GB
- United Kingdom
- Prior art keywords
- use according
- ophthalmic condition
- compound
- ifenprodil
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- UYNVMODNBIQBMV-UHFFFAOYSA-N 4-[1-hydroxy-2-[4-(phenylmethyl)-1-piperidinyl]propyl]phenol Chemical compound C1CC(CC=2C=CC=CC=2)CCN1C(C)C(O)C1=CC=C(O)C=C1 UYNVMODNBIQBMV-UHFFFAOYSA-N 0.000 title claims abstract description 18
- 229960003998 ifenprodil Drugs 0.000 title claims abstract description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract description 14
- 201000010099 disease Diseases 0.000 title abstract description 12
- 208000002780 macular degeneration Diseases 0.000 claims abstract description 11
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims abstract description 10
- 206010013774 Dry eye Diseases 0.000 claims abstract description 10
- 206010064930 age-related macular degeneration Diseases 0.000 claims abstract description 10
- 208000010412 Glaucoma Diseases 0.000 claims abstract description 8
- 206010012689 Diabetic retinopathy Diseases 0.000 claims abstract description 7
- 206010046851 Uveitis Diseases 0.000 claims abstract description 7
- 206010058202 Cystoid macular oedema Diseases 0.000 claims abstract description 5
- 208000001351 Epiretinal Membrane Diseases 0.000 claims abstract description 5
- 208000001344 Macular Edema Diseases 0.000 claims abstract description 5
- 208000031471 Macular fibrosis Diseases 0.000 claims abstract description 5
- 201000010206 cystoid macular edema Diseases 0.000 claims abstract description 5
- 208000002367 Retinal Perforations Diseases 0.000 claims abstract description 3
- 208000029233 macular holes Diseases 0.000 claims abstract description 3
- 239000012528 membrane Substances 0.000 claims abstract description 3
- 230000000694 effects Effects 0.000 claims description 11
- 150000001875 compounds Chemical class 0.000 claims description 9
- 102000004127 Cytokines Human genes 0.000 claims description 8
- 108090000695 Cytokines Proteins 0.000 claims description 8
- 239000003102 growth factor Substances 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 5
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 claims description 4
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 4
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 4
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 4
- 230000000699 topical effect Effects 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 3
- 239000007924 injection Substances 0.000 claims description 3
- 230000000649 photocoagulation Effects 0.000 claims description 3
- 150000003431 steroids Chemical class 0.000 claims description 3
- 238000002560 therapeutic procedure Methods 0.000 claims description 3
- TYNLGDBUJLVSMA-UHFFFAOYSA-N 4,5-diacetyloxy-9,10-dioxo-2-anthracenecarboxylic acid Chemical compound O=C1C2=CC(C(O)=O)=CC(OC(C)=O)=C2C(=O)C2=C1C=CC=C2OC(=O)C TYNLGDBUJLVSMA-UHFFFAOYSA-N 0.000 claims description 2
- 108060003345 Adrenergic Receptor Proteins 0.000 claims description 2
- 102000017910 Adrenergic receptor Human genes 0.000 claims description 2
- YUWPMEXLKGOSBF-GACAOOTBSA-N Anecortave acetate Chemical compound O=C1CC[C@]2(C)C3=CC[C@]4(C)[C@](C(=O)COC(=O)C)(O)CC[C@H]4[C@@H]3CCC2=C1 YUWPMEXLKGOSBF-GACAOOTBSA-N 0.000 claims description 2
- 102000004550 Angiostatic Proteins Human genes 0.000 claims description 2
- 108010017551 Angiostatic Proteins Proteins 0.000 claims description 2
- 102000012936 Angiostatins Human genes 0.000 claims description 2
- 108010079709 Angiostatins Proteins 0.000 claims description 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims description 2
- ZCVMWBYGMWKGHF-UHFFFAOYSA-N Ketotifene Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 ZCVMWBYGMWKGHF-UHFFFAOYSA-N 0.000 claims description 2
- 239000004098 Tetracycline Substances 0.000 claims description 2
- 239000000674 adrenergic antagonist Substances 0.000 claims description 2
- 229960001232 anecortave Drugs 0.000 claims description 2
- 230000000964 angiostatic effect Effects 0.000 claims description 2
- 239000003242 anti bacterial agent Substances 0.000 claims description 2
- 230000001387 anti-histamine Effects 0.000 claims description 2
- 229940088710 antibiotic agent Drugs 0.000 claims description 2
- 229940125715 antihistaminic agent Drugs 0.000 claims description 2
- 239000000739 antihistaminic agent Substances 0.000 claims description 2
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 claims description 2
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 claims description 2
- 229960004590 diacerein Drugs 0.000 claims description 2
- 229960001259 diclofenac Drugs 0.000 claims description 2
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims description 2
- 229940124307 fluoroquinolone Drugs 0.000 claims description 2
- 229960002390 flurbiprofen Drugs 0.000 claims description 2
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 claims description 2
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims description 2
- 229960004752 ketorolac Drugs 0.000 claims description 2
- OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 claims description 2
- 229960004958 ketotifen Drugs 0.000 claims description 2
- 150000002617 leukotrienes Chemical class 0.000 claims description 2
- 229960003088 loratadine Drugs 0.000 claims description 2
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 claims description 2
- 229960004584 methylprednisolone Drugs 0.000 claims description 2
- 239000002571 phosphodiesterase inhibitor Substances 0.000 claims description 2
- 235000019364 tetracycline Nutrition 0.000 claims description 2
- 150000003522 tetracyclines Chemical class 0.000 claims description 2
- 229940040944 tetracyclines Drugs 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- UHTHHESEBZOYNR-UHFFFAOYSA-N vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 claims description 2
- 229960000241 vandetanib Drugs 0.000 claims description 2
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 abstract description 9
- 230000004054 inflammatory process Effects 0.000 abstract description 9
- 206010038886 Retinal oedema Diseases 0.000 abstract description 4
- 230000033115 angiogenesis Effects 0.000 abstract description 3
- 201000010183 Papilledema Diseases 0.000 abstract description 2
- 208000035475 disorder Diseases 0.000 abstract description 2
- 230000001575 pathological effect Effects 0.000 abstract description 2
- 201000011195 retinal edema Diseases 0.000 abstract description 2
- 230000002207 retinal effect Effects 0.000 abstract 1
- 206010038923 Retinopathy Diseases 0.000 description 7
- 210000001525 retina Anatomy 0.000 description 5
- 201000004569 Blindness Diseases 0.000 description 4
- 208000017442 Retinal disease Diseases 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 229940121363 anti-inflammatory agent Drugs 0.000 description 3
- 239000002260 anti-inflammatory agent Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 210000000554 iris Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 210000001328 optic nerve Anatomy 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 229940124549 vasodilator Drugs 0.000 description 3
- 239000003071 vasodilator agent Substances 0.000 description 3
- 208000002177 Cataract Diseases 0.000 description 2
- 206010022557 Intermediate uveitis Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 229940124599 anti-inflammatory drug Drugs 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 210000003161 choroid Anatomy 0.000 description 2
- 210000004240 ciliary body Anatomy 0.000 description 2
- 230000003412 degenerative effect Effects 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- -1 steroid steroid Chemical class 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 208000002691 Choroiditis Diseases 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 206010012688 Diabetic retinal oedema Diseases 0.000 description 1
- 208000001860 Eye Infections Diseases 0.000 description 1
- 208000020564 Eye injury Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102100021090 Homeobox protein Hox-A9 Human genes 0.000 description 1
- 101001083156 Homo sapiens Homeobox protein Hox-A1 Proteins 0.000 description 1
- 101001083164 Homo sapiens Homeobox protein Hox-A10 Proteins 0.000 description 1
- 101001083158 Homo sapiens Homeobox protein Hox-A11 Proteins 0.000 description 1
- 101001083162 Homo sapiens Homeobox protein Hox-A13 Proteins 0.000 description 1
- 101000962622 Homo sapiens Homeobox protein Hox-A3 Proteins 0.000 description 1
- 101001077578 Homo sapiens Homeobox protein Hox-A4 Proteins 0.000 description 1
- 101001077568 Homo sapiens Homeobox protein Hox-A5 Proteins 0.000 description 1
- 101001045083 Homo sapiens Homeobox protein Hox-A6 Proteins 0.000 description 1
- 101001045116 Homo sapiens Homeobox protein Hox-A7 Proteins 0.000 description 1
- 101001041174 Homo sapiens Homeobox protein Hox-A9 Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010022941 Iridocyclitis Diseases 0.000 description 1
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 1
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 208000003971 Posterior uveitis Diseases 0.000 description 1
- 206010038848 Retinal detachment Diseases 0.000 description 1
- 206010038910 Retinitis Diseases 0.000 description 1
- 108700012920 TNF Proteins 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 208000000208 Wet Macular Degeneration Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 201000004612 anterior uveitis Diseases 0.000 description 1
- 230000003092 anti-cytokine Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 201000011190 diabetic macular edema Diseases 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000004406 elevated intraocular pressure Effects 0.000 description 1
- 206010014801 endophthalmitis Diseases 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 102000035122 glycosylated proteins Human genes 0.000 description 1
- 108091005608 glycosylated proteins Proteins 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000004410 intraocular pressure Effects 0.000 description 1
- 206010023332 keratitis Diseases 0.000 description 1
- 201000010666 keratoconjunctivitis Diseases 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 201000007407 panuveitis Diseases 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000004264 retinal detachment Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 210000002820 sympathetic nervous system Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 210000001745 uvea Anatomy 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 210000004127 vitreous body Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Ifenprodil has been found to be useful in the treatment of ophthalmic disease states characterized by ocular inflammation, dry eye disorders, increased ocular pressure, pathologic ocular angiogenesis and retinal or sub-retinal edema. Examples of such diseases include age-related macular degeneration, diabetic retinopathy, choroidal neovascular membrane, cystoid macular edema, epi-retinal membrane, macular hole, dry eye, uveitis or glaucoma.
Description
<p>1 2432526 The Treatment of Ophthalmic Diseases</p>
<p>Field of the Invention</p>
<p>This invention relates to the use of Ifenprodil and isomers and metabolites of Ifenprodil for the treatment of ophthalmic diseases characterized by ocular inflammation, dry eye disorders, increased intra-ocular pressure, pathologic ocular angiogenesis and/or retina or sub-retinal edema.</p>
<p>Background</p>
<p>Diseases and degenerative conditions of the optic nerve and retina are the leading causes of blindness in the world. A significant degenerative condition of the retina is age-related macular degeneration (ARMD). ARMD is the most common cause of blindness in people over 50 in the USA and its prevalence increases with age. ARMD is classified as either wet (neovascular) or dry (non-neovascular) where the dry form of the disease is the most common. Macular degeneration occurs when the central retina has become distorted and thinned usually associated with age but also charactensed by intra-ocular inflammation and angiogenesis (wet ARMD only) and/or intra-ocular infection.</p>
<p>Retinopathy associated with diabetes is a leading cause of blindness in type I diabetes, and is also common in type II diabetes. The degree of retinopathy depends on the duration of diabetes, and generally begins to occur ten or more years after onset of diabetes. Diabetic retinopathy may be classified as non-proliferative, where the retinopathy is charactensed by increased capillary permeability, edema and exudates, or proliferative, where the retinopathy is characterised by neovasculansation extending from the retina to the vitreous, scarring, deposit of fibrous tissue and the potential for retinal detachment. Diabetic retinopathy is believed to be caused by the development of glycosylated proteins due to high blood glucose. The subsequent generation of free-radicals resulting in oxidative tissue damage, local inflammation and production of growth factors (such as VEGF and FGF) and inflammatory mediators leads to inappropriate neovasculansation in common with the wet form of ARMD. Several other less common retinopathies include choroidal neovascular membrane (CNVM), cystoid macular edema (CME), epi-retinal membrane (ERM) and macular hole. Today, no drugs approved for the treatment of diabetic retinopathy or macular edema. The current standard treatment is laser photocoagulation which by destroying local tissue, deceases the production of cytokines and growth factors but is unfortunately cytodestructive and causes permanent impairment of vision. These neovasular diseases have the potential to be treated with angiostatic agents in combination with anti-inflammatory drugs.</p>
<p>Dry eye, or keratoconjunctivitis, is a common ophthalmological disease affecting millions of Americans eath year. The condition is particularly prevalent in post-menopausal women due to hormonal changes caused by the cessation of fertility. Dry eye is primarily caused by the break-down of the pre-ocular tear film which results in dehydration of the exposed outer surface. There is a strong rationale that ocular inflammation as a result of pro-inflammatory cytokines and growth factors play a major role in the underlying causes of dry eye. As such locally administered anti-cytokine or general anti-inflammatory agents are often used in the treatment of dry eye.</p>
<p>Another disease of the interior of the eye is uveitis, or inflammation of the uveal tract. The uveal tract (uvea) is composed of the iris, ciliary body and choroid.</p>
<p>Uveitis may be caused by trauma, infection or surgery and can affect any age group.</p>
<p>The disease is classified anatomically as anterior, intermediate, posterior or diffuse.</p>
<p>Anterior uveitis affects the anterior portion of the eye including the iris. Intermediate uveitis, also called peripheral uveitis, is centred in the area immediately behind the iris and lens in the region of the ciliary body. Posterior uveitis may also constitute a form of retinitis, or it may affect the choroids and the optic nerve. Diffuse uveitis involves all parts of the eye. The most common treatment of uveitis is with locally administered glucocorticosteroids often in combination with other anti-inflammatory drugs. Although these drugs are effective in the treatment of many forms of ocular inflammation they have several side-effects including endophthalmitis, cataracts and elevated intra-ocular pressure (lOP). There is a need for potent anti-inflammatory agents with an improved side effect profile, the so-called non-steroid steroid, for the treatment of ophthalmic inflammation and edema.</p>
<p>Glaucoma is made up of a collection of eye diseases that cause vision loss by damage to the optic nerve. Elevated lOP due to inadequate ocular drainage is the primary cause of glaucoma. Glaucoma often develops as the eye ages, or it can occur as the result of an eye injury, inflammation, tumour or in advanced cases of cataract or diabetes. As discussed above it can also be caused by the increase in lOP caused by treatment with steroids. Drug therapies that are proven to be effective in glaucoma reduce lOP either by deceasing vitreous humor production or by facilitating ocular draining. Such agents are often vasodilators and as such act on the sympathetic nervous system and include adrenergic antagonists. There is a need for agents that can be delivered locally to the eye with minimal systemic side effects.</p>
<p>The use of ifenprodil (1) and isomers of ifenprodil for the treatment of general inflammatory conditions and pain is the subject of a separate application HOX1 Ifenprodil (1)</p>
<p>Summary of Invention</p>
<p>Surprisingly it has been found that ifenprodil (1), a drug used as a cerebral vasodilator and NMDA antagonist, is a potent anti-inflammatory agent. Furthermore, diastereoisomers of ifenprodil which have reduced primary activity against alpha-adrenoreceptors and the NMDA receptor retain this anti-inflammatory action.</p>
<p>Ifenprodil (1) suffers from extensive first pass metabolism which makes the compound ideal for topical delivery where systemic side effects can be minimised.</p>
<p>The unexpected profile of ifenprodil and its isomers is consistent with the non- steroid steroid and provides cytokine modulation with down regulation of pro-inflammatory cytokines (such as TNFa and IL-1f3) and growth factors involved in neovascularisation (such as FGF and VEGF) and upregulation of anti-inflammatory cytokines (such as IL-b) in combination with alpha-adrenoreceptor blocking activity resulting in vasodilation.</p>
<p>Description of the Invention</p>
<p>In this specification, reference to "treatment" includes any form of therapy, including curative and prophylactic.</p>
<p>Local administration of Ifenprodil (1), or an isomer of ifenprodil, or a metabolite of ifenprodil to the eye will allow the treatment of a range of ophthalmic diseases such as ARMD, retinopathies (including diabetic retinopathy), dry eye, uveitis and even glaucoma with minimal systemic side-effects.</p>
<p>It is understood that the invention refers to free-base, salts, e.g. the hydrochloride and hemi-tartarate, metabolites and pro-drugs thereof, as well as any diastereomers and enantiomers of (1).</p>
<p>According to another aspect of the invention, some of the isomers of formula (1) have vasodilator properties by antagonism at alpha adrenoceptors. These agents while being particularly interesting in the treatment of glaucoma represent the least preferred isomers for the treatment of ocular inflammatory diseases.</p>
<p>However, according to an additional aspect of the invention, the preferred diastereomer or enantiomer of (1) for the treatment of ARMD, retinopathies (including diabetic retinopathy), dry eye and uveitis has cytokine/growth factor modulatory activity but little or no activity at the alpha adrenoreceptors. This activity may be determined by use of the appropriate in vitro and in vivo assays.</p>
<p>The compounds of formula (1) may be used according to the invention when the patient is also administered or in combination with another therapeutic agent selected from angiostatic peptides, such as angiostatin; angiostatic steroids, such as anecortave acetate; modulators of VEGF or FGF, such as zactima; non-steroidal anti-inflammatory drugs (NSAID5) formulated for ocular use such as flurbiprofen, diclofenac and ketorolac; glucocorticosteroids, such as methylprednisolone; leukotriene modulators such as zilueton; anti-histamines such as cetinzine, loratidine, ketotifen and the like; and general cytokine/growth factor modulating agents such as cyclosporin A, diacerein, tetracyclines, fluoroquinolone antibiotics, quinoline antimalanals, statins, phosphodiesterase inhibitors and the like.</p>
<p>Compounds of formula (1) may also be administered before, during or after laser photocoagulation therapy.</p>
<p>The preferred route of administration is topical to the eye although other forms of application could include intraocular injection. An additional aspect of the invention describes formulations of compounds of general formula (1) suitable for topical application to the eye or intraocular injection. The dose of the active agent will depend on the nature and degree of the condition, the age and condition of the patient and other factors known to those skilled in the art. A typical dose is 0.01-mg given one to three times per day.</p>
Claims (1)
- <p>Claims 1. Use of ifenprodil for the treatment of an ophthalmiccondition.</p><p>2. Use according to claim 1, wherein the ophthalmic condition is age-related macular degeneration (ARMD).</p><p>3. Use according to claim 1, wherein the ophthalmic condition is diabetic retinopathy.</p><p>4. Use according to claim 1, wherein the ophthalmic condition is choroidal neovascular membrane (CNVM), cystoid macular edema (CME), epi-retinal membrane (ERM) or macular hole.</p><p>5. Use according to claim 1, wherein the ophthalmic condition is dry eye.</p><p>6. Use according to claim 1, wherein the ophthalmic condition is uveitis.</p><p>7. Use according to any preceding claim, wherein the compound is in the form of the enantiomer or diastereomer that has relatively little or no activity at the a adrenoceptor.</p><p>8. Use according to claim 1, wherein the ophthalmic condition is glaucoma.</p><p>9. Use according to claim 8, wherein the compound is in the form of the enantiomer or diastereomer that also has a adrenoceptor antagonist activity.</p><p>10. Use according to any preceding claim, wherein the compound is to be administered before, during or after laser photocoagulation therapy.</p><p>11. Use according to any preceding claim, wherein the compound is formulated for topical application to the eye or for intraocular injection.</p><p>12. Use according to any preceding claim, wherein the patient to be treated is also administered another therapeutic agent selected from angiostatic peptides, such as angiostatin; angiostatic steroids, such as anecortave acetate; modulators of VEGF or FGF, such as zactima; non-steroidal anti-inflammatory drugs (NSAIDs) formulated for ocular use such as flurbiprofen, diclofenac and ketorolac; glucocorticosteroids, such as methylprednisolone; leukotriene modulators such as zilueton; anti-histamines such as cetinzine, loratidine, ketotifen and the like; and general cytokine/growth factor modulating agents such as cyclosponn A, diacerein, tetracyclines, fluoroquinolone antibiotics, quinoline antimalanals, statins, phosphodiesterase inhibitors and the like.</p><p>13. Use according to claim 12 wherein compound (1) and said another agent are provided in combination.</p>
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0523961A GB2432526A (en) | 2005-11-24 | 2005-11-24 | Use of ifenprodil for the treatment of ophthalmic diseases |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0523961A GB2432526A (en) | 2005-11-24 | 2005-11-24 | Use of ifenprodil for the treatment of ophthalmic diseases |
Publications (2)
Publication Number | Publication Date |
---|---|
GB0523961D0 GB0523961D0 (en) | 2006-01-04 |
GB2432526A true GB2432526A (en) | 2007-05-30 |
Family
ID=35601152
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB0523961A Withdrawn GB2432526A (en) | 2005-11-24 | 2005-11-24 | Use of ifenprodil for the treatment of ophthalmic diseases |
Country Status (1)
Country | Link |
---|---|
GB (1) | GB2432526A (en) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011137363A1 (en) * | 2010-04-30 | 2011-11-03 | Allergan, Inc. | Novel treatment for age related macular degeneration and ocular ischemic disease associated with complement activation by targeting 5-lipoxygenase |
CN103007284A (en) * | 2013-01-16 | 2013-04-03 | 闫莹 | Application of HMGCoA reductase inhibitor in preparation of medicine used for treating xerophthalmia |
WO2013095320A1 (en) * | 2011-12-23 | 2013-06-27 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Flurbiprofen formulations |
WO2013100882A2 (en) * | 2011-12-27 | 2013-07-04 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Combinations of diacerein and non-steroidal inflammation drugs |
WO2013100881A3 (en) * | 2011-12-27 | 2013-10-10 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Combined pharmaceutical formulation containing diacerein |
WO2013095319A3 (en) * | 2011-12-23 | 2013-10-10 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Formulations of flurbiprofen and diacerein |
WO2013095318A3 (en) * | 2011-12-23 | 2013-12-05 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Orally-disintegrating formulations of flurbiprofen |
WO2014068007A1 (en) * | 2012-10-30 | 2014-05-08 | Pharnext | Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level |
US10617689B2 (en) | 2013-10-30 | 2020-04-14 | Pharnext | Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0728480A1 (en) * | 1995-02-24 | 1996-08-28 | Rohto Pharmaceutical Co., Ltd. | Use of ifenprodil for treatment of elevated intraocular pressure |
WO1997002823A1 (en) * | 1994-07-06 | 1997-01-30 | Synthelabo | Use of polyamine antagonists for the treatment of glaucoma |
WO1997018812A1 (en) * | 1995-11-17 | 1997-05-29 | Alcon Laboratories, Inc. | Combination therapy for treating glaucoma |
WO1997024123A1 (en) * | 1996-01-02 | 1997-07-10 | Synthelabo | Use of polyamine site antagonist for the manufacture of a medicament for the treatment of ischemic disorders of the eye |
-
2005
- 2005-11-24 GB GB0523961A patent/GB2432526A/en not_active Withdrawn
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997002823A1 (en) * | 1994-07-06 | 1997-01-30 | Synthelabo | Use of polyamine antagonists for the treatment of glaucoma |
EP0728480A1 (en) * | 1995-02-24 | 1996-08-28 | Rohto Pharmaceutical Co., Ltd. | Use of ifenprodil for treatment of elevated intraocular pressure |
WO1997018812A1 (en) * | 1995-11-17 | 1997-05-29 | Alcon Laboratories, Inc. | Combination therapy for treating glaucoma |
WO1997024123A1 (en) * | 1996-01-02 | 1997-07-10 | Synthelabo | Use of polyamine site antagonist for the manufacture of a medicament for the treatment of ischemic disorders of the eye |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011137363A1 (en) * | 2010-04-30 | 2011-11-03 | Allergan, Inc. | Novel treatment for age related macular degeneration and ocular ischemic disease associated with complement activation by targeting 5-lipoxygenase |
WO2013095319A3 (en) * | 2011-12-23 | 2013-10-10 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Formulations of flurbiprofen and diacerein |
WO2013095318A3 (en) * | 2011-12-23 | 2013-12-05 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Orally-disintegrating formulations of flurbiprofen |
WO2013095320A1 (en) * | 2011-12-23 | 2013-06-27 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Flurbiprofen formulations |
WO2013100882A3 (en) * | 2011-12-27 | 2013-12-05 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Combinations of diacerein and non-steroidal inflammation drugs |
WO2013100881A3 (en) * | 2011-12-27 | 2013-10-10 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Combined pharmaceutical formulation containing diacerein |
WO2013100882A2 (en) * | 2011-12-27 | 2013-07-04 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Combinations of diacerein and non-steroidal inflammation drugs |
WO2014068007A1 (en) * | 2012-10-30 | 2014-05-08 | Pharnext | Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level |
AU2013340826B2 (en) * | 2012-10-30 | 2018-07-26 | Pharnext | Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level |
US10092554B2 (en) | 2012-10-30 | 2018-10-09 | Pharnext | Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level |
EA031798B1 (en) * | 2012-10-30 | 2019-02-28 | Фарнекст | Use of ifenprodil for the treatment of diabetes |
US10596160B2 (en) | 2012-10-30 | 2020-03-24 | Pharnext | Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level |
CN103007284A (en) * | 2013-01-16 | 2013-04-03 | 闫莹 | Application of HMGCoA reductase inhibitor in preparation of medicine used for treating xerophthalmia |
US10617689B2 (en) | 2013-10-30 | 2020-04-14 | Pharnext | Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level |
Also Published As
Publication number | Publication date |
---|---|
GB0523961D0 (en) | 2006-01-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7278257B2 (en) | Treatment of eye conditions such as macular degeneration, glaucoma, and diabetic retinopathy with pharmaceutical agents that eliminate senescent cells | |
WO2010125416A1 (en) | Drug delivery to the anterior and posterior segments of the eye | |
US20220175727A1 (en) | Anti-Inflammatory and Mydriatic Intracameral Solutions for Inhibition of Postoperative Ocular Inflammatory Conditions | |
GB2432526A (en) | Use of ifenprodil for the treatment of ophthalmic diseases | |
US20230103975A1 (en) | Injector for delivering implants | |
Sakai et al. | Ciliochoroidal effusion induced by topical latanoprost in a patient with sturge-weber syndrome | |
US20090137686A1 (en) | Treatment of Ophthalmic Diseases | |
JP2016538292A (en) | Methods of treatment of ophthalmic conditions with sustained drug delivery implants | |
Scherer et al. | Effect of latanoprost on intraocular pressure following cataract extraction | |
Laroche et al. | Case report: Cataract extraction/lensectomy, excisional goniotomy and transscleral cyclophotocoagulation: Affordable combination MIGS for plateau iris glaucoma | |
CA2453442A1 (en) | Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases | |
JP4150846B2 (en) | Retinal choroidal disease treatment containing steroid as active ingredient | |
US20240374372A1 (en) | Ocular device and methods | |
Mackert | Cataract and Glaucoma | |
AU2022334744A1 (en) | Ocular device and methods | |
Diana et al. | Comparison of Topical Nepafenac 0.1% and Prednisolone Acetate 1% as an Anti-Inflammatory after Vitrectomy in Rhegmatogenous Retinal Detachment | |
CN118159223A (en) | Ocular devices and methods | |
Shetty et al. | NEOVASCULAR GLAUCOMA | |
Park et al. | Conjunctival nevus-like lesions originating from a sclerotomy site after 23-gauge transconjunctival sutureless vitrectomy | |
Schlote et al. | Treatment of rubeotic secondary glaucoma | |
Ichhpujani et al. | Modern Trabeculectomy | |
Sánchez et al. | Treatment of Inflammation Secondary to Vitreoretinal Surgery | |
Adelman et al. | Posterior Segment Complications of LASIK |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WAP | Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1) |